Latest Darbepoetin alfa Stories
THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the U.S.
Cites increased risk of cardiovascular events when used to treat chronic kidney disease SILVER SPRING, Md., June 24, 2011 /PRNewswire-USNewswire/ -- The U.S.
THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago.
Patients with diabetes, kidney disease and anemia who donâ€™t respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death.
BANGALORE, India, December 8, 2010 /PRNewswire/ -- AVESTHAGEN LIMITED, a leading knowledge based life sciences company pioneering the convergence between Food, Pharma and Population Genetics, today announced the completion of manufacturing of the clinical grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to Darbepoetin alfa), which will now be moving into Clinical Trials.
THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key NplateÂ® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.
EXTON, Pa., Oct. 27 /PRNewswire/ -- BioTrends Research Group, Inc. released two syndicated Nephrology TreatmentTrendsÂ® publications (TreatmentTrendsÂ®: US Nephrology Q310 and TreatmentTrendsÂ®: Renal Dietitians 2010).
THOUSAND OAKS, Calif., Oct.
THOUSAND OAKS, Calif., Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.